Use of nonantiarrhythmic drugs for prevention of sudden cardiac death

被引:43
作者
Alberte, C [1 ]
Zipes, DP [1 ]
机构
[1] Indiana Univ, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA
关键词
ventricular fibrillation; sudden death; drugs;
D O I
10.1046/j.1540-8167.14.s9.23.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Nonantiarrhythmic Drugs for SCD Prevention. It is of interest that the drugs having the most significant impact on total and sudden death mortality are those without direct electrophysiologic actions on myocardial excitable tissue. This observation may provide insight into mechanisms responsible for ventricular tachyarrhythmias causing cardiac arrest. One way to think about ventricular fibrillation is that it is the final common pathway of an electrically unstable heart. After all, the heart can "die" in only three major ways: electromechanical dissociation, asystole and heart block, and ventricular fibrillation, with the latter most common. It is the "upstream" events provoking the electrical instability that these drugs probably act upon (i.e., ischemia, fibrosis). Although we unquestionably need to pursue investigations into the electrophysiology of these ventricular tachyarrhythmias, more studies need to investigate the drugs affecting upstream events, because these agents appear to yield the greatest dividends, at least for the present. This article reviews these drugs and how they may be effective.
引用
收藏
页码:S87 / S95
页数:9
相关论文
共 122 条
[21]  
CHAMBERLAIN DA, 1990, LANCET, V335, P427
[22]   Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes [J].
Cheetham, C ;
O'Driscoll, G ;
Stanton, K ;
Taylor, R ;
Green, D .
CLINICAL SCIENCE, 2001, 100 (01) :13-17
[23]  
Christensen JH, 1996, BMJ-BRIT MED J, V312, P677, DOI 10.1136/bmj.312.7032.677
[24]   Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction [J].
Christensen, JH ;
Korup, E ;
Aaroe, J ;
Toft, E ;
Moller, J ;
Rasmussen, K ;
Dyerberg, J ;
Schmidt, EB .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 79 (12) :1670-+
[25]   C-reactive protein elevation in patients with atrial arrhythmias - Inflammatory mechanisms and persistence of atrial fibrillation [J].
Chung, MK ;
Martin, DO ;
Sprecher, D ;
Wazni, O ;
Kanderian, A ;
Carnes, CA ;
Bauer, JA ;
Tchou, PJ ;
Niebauer, MJ ;
Natale, A ;
Van Wagoner, DR .
CIRCULATION, 2001, 104 (24) :2886-2891
[26]   VALIDATION OF PRIMARY AND SECONDARY OUTCOMES AND CLASSIFICATION OF MODE OF DEATH AMONG PATIENTS WITH CLINICAL-EVIDENCE OF HEART-FAILURE AFTER A MYOCARDIAL-INFARCTION - A REPORT FROM THE ACUTE INFARCTION RAMIPRIL EFFICACY (AIRE) STUDY INVESTIGATORS [J].
CLELAND, JGF ;
ERHARDT, L ;
HALL, AS ;
WINTER, C ;
BALL, SG .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1993, 22 :S22-S27
[27]  
CLELAND JGF, 1993, BRIT HEART J, V69, P512
[28]   Low-molecular-weight heparins in non-ST-segment elevation ischemia: The ESSENCE trial [J].
Cohen, M ;
Demers, C ;
Gurfinkel, EP ;
Turpie, AGG ;
Fromell, GJ ;
Goodman, S ;
Langer, A ;
Califf, RM ;
Fox, KAA ;
Premmereur, J ;
Bigonzi, F .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 82 (5B) :19L-24L
[29]   A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease [J].
Cohen, M ;
Demers, C ;
Gurfinkel, EP ;
Turpie, AGG ;
Fromell, GJ ;
Goodman, S ;
Langer, A ;
Califf, RM ;
Fox, KAA ;
Premmereur, J ;
Bigonzi, F .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (07) :447-452
[30]   A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure [J].
Cohn, JN ;
Tognoni, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (23) :1667-1675